5-氟-2-咪唑苯胺 | 251649-52-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氟-2-咪唑苯胺
• 中文别名: 5-氟-2-(咪唑-1-基)苯胺；5-氟-2-(1H-咪唑-1-基)苯胺
• 英文名称: 1-(2-amino-4-fluorophenyl)-1H-imidazole
• 英文别名: 5-Fluoro-2-(1H-Imidazol-1-Yl)Aniline；5-fluoro-2-imidazol-1-ylaniline
• CAS: 251649-52-2
• 化学式: C₉H₈FN₃
• mdl: MFCD02180945
• 分子量: 177.181
• InChiKey: DCSCOECASPLFFN-UHFFFAOYSA-N

物化性质

• 熔点：
  127 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  5-氟-2-咪唑苯胺 在 三氯氧磷 作用下， 以 N,N-二甲基苯胺 、 甲苯 为溶剂， 反应 12.5h， 生成 7-Fluoro-4-(4-methyl-piperazin-1-yl)-imidazo[1,2-a]quinoxaline
  参考文献：
  名称：

  吡咯并喹喔啉衍生物作为高亲和力和选择性5-HT（3）受体激动剂：合成，进一步的结构活性关系和生物学研究。

  摘要：

  描述了一系列新型吡咯并喹喔啉和杂芳族相关衍生物的合成，药理评价和构效关系（SAR）。新的吡咯并喹喔啉相关配体在大鼠皮层，表达高密度5-HT（3）受体的组织中以及在NG108-15细胞上进行了测试，并在低纳摩尔或亚纳摩尔范围内表现出IC（50）值，方法是通过抑制[（3）H] zacopride结合。本文详述的SAR研究描述了改善亲和力所需的许多结构特征。一些配体被用作“分子尺度”，以探测5-HT（3）受体裂隙中亲脂性口袋L1，L2和L3的空间尺寸，而7-OH吡咯并喹喔啉类似物被设计用于研究与可能与5-羟色胺羟基相互作用的假定受体位点H1的氢键作用。最活跃的吡咯并喹喔啉衍生物对5-HT（3）受体显示亚纳摩尔亲和力。在功能研究中（[[14] C]胍在NG108-15杂化细胞中的体外积累试验），大多数受试化合物均显示出明确的5-HT（3）激动剂特性，而另一些则为部分激动剂。关于5-HT（3）亲和力

  DOI：

  10.1021/jm990151g
• 作为产物：
  描述：

  2,5-二氟硝基苯 在 tin(ll) chloride 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 54.0h， 生成 5-氟-2-咪唑苯胺
  参考文献：
  名称：

  吡咯并喹喔啉衍生物作为高亲和力和选择性5-HT（3）受体激动剂：合成，进一步的结构活性关系和生物学研究。

  摘要：

  描述了一系列新型吡咯并喹喔啉和杂芳族相关衍生物的合成，药理评价和构效关系（SAR）。新的吡咯并喹喔啉相关配体在大鼠皮层，表达高密度5-HT（3）受体的组织中以及在NG108-15细胞上进行了测试，并在低纳摩尔或亚纳摩尔范围内表现出IC（50）值，方法是通过抑制[（3）H] zacopride结合。本文详述的SAR研究描述了改善亲和力所需的许多结构特征。一些配体被用作“分子尺度”，以探测5-HT（3）受体裂隙中亲脂性口袋L1，L2和L3的空间尺寸，而7-OH吡咯并喹喔啉类似物被设计用于研究与可能与5-羟色胺羟基相互作用的假定受体位点H1的氢键作用。最活跃的吡咯并喹喔啉衍生物对5-HT（3）受体显示亚纳摩尔亲和力。在功能研究中（[[14] C]胍在NG108-15杂化细胞中的体外积累试验），大多数受试化合物均显示出明确的5-HT（3）激动剂特性，而另一些则为部分激动剂。关于5-HT（3）亲和力

  DOI：

  10.1021/jm990151g

文献信息

• Nf-kb activation inhibitors
  申请人：Muto Susumu

  公开号：US20060089395A1

  公开（公告）日：2006-04-27

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  一种药物具有抑制NF-κB活化作用，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基，其可以被取代，但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基，圆圈(2)}未取代的噻唑-2-基团，或者圆圈(3)}未取代的苯并噻唑-2-基团时，不包括该化合物，环Z代表一个芳香烃，除了由公式—O-A所表示的基团外，它也可以有一个或多个取代基，其中A具有与上述定义相同的含义，公式—CONH-E所表示的基团E具有与上述定义相同的含义。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Medicament for treatment of diabetes
  申请人：Muto Susumu

  公开号：US20060111409A1

  公开（公告）日：2006-05-25

  A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗糖尿病或糖尿病并发症的药物，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一： 其中，X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳基，除了由公式—O—A所表示的基团外，该芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者可以具有一个或多个取代基的杂环芳基，除了由公式—O—A所表示的基团外，该杂环芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同。
• Antiallergic
  申请人：Muto Susumu

  公开号：US20060122243A1

  公开（公告）日：2006-06-08

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳烃，除了由公式-O-A所表示的基团外，该芳烃还可以具有公式—X-E所表示的基团，其中每个X和E具有上述定义的相同含义，或者该环可以具有一个或多个取代基，除了由公式—O-A所表示的基团外，该环还可以具有公式—X-E所表示的基团，其中A具有上述定义的相同含义，X和E分别具有上述定义的相同含义。
• Medicament for treatment of cancer
  申请人：Muto Susumu

  公开号：US20060014811A1

  公开（公告）日：2006-01-19

  A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  预防和/或治疗癌症及类似疾病的药物，其活性成分为以下通式（I）所代表的化合物中所选的一种或其药学上可接受的盐，以及其水合物和溶剂化物：其中A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基，或单环或融合的多环杂环芳基，可以被取代，但其中异杂环基团为circle around (1)}在公式（I）中直接结合—CONH—基团的环为苯环的融合多环杂环芳基，circle around (2)}未取代的噻唑-2-基团，或circle around (3)}未取代的苯并噻唑-2-基团被排除，环Z代表一个芳烃，除了由公式—O-A所代表的基团和由公式—CONH-E所代表的基团以外，它可以有一个或多个取代基，其中A具有上述定义的相同含义，E具有上述定义的相同含义，或者它可以是一个具有上述定义的相同含义的杂芳烃，它可以有一个或多个取代基。